Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.73 |
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039248 | 0.90 | AURKA (0.74) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL2049234 | 0.89 | PDGFRB (0.79) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL3428320 | 0.89 | PDGFRB (0.79) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6026826 | 0.89 | PDGFRB (0.79) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6027929 | 0.89 | AURKA (0.60) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6089265 | 0.89 | AURKA (0.73) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6027367 | 0.89 | AURKA (0.73) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6091927 | 0.89 | AURKA (0.57) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6027680 | 0.88 | AURKA (0.56) | AURKACSF1RPDGFRBKITPDGFRA | |
| SCHEMBL6027507 | 0.88 | AURKA (0.59) | AURKACSF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | AURKA 1/4885CSF1R 3068/4885PDGFRB 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.